Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (Nasdaq: TNGX) is a clinical-stage biopharmaceutical company focused on precision oncology, developing targeted cancer therapies through a synthetic lethality platform. The company entered the public markets in 2021 via its merger with BCTG Acquisition Corp., a blank-check vehicle sponsored by BCTG Management LLC, entities affiliated with Boxer Capital and TCG Crossover. Following the de-SPAC transaction, Tango has continued its SEC reporting obligations as a listed issuer, most recently filing an 8-K on June 4, 2026, under accession number 0001193125-26-257760. For full filing history, sponsor details, and real-time SPAC analytics on TNGX, sign up for complete data access at SpacDesk.